RECRUITING

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.

Official Title

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

Quick Facts

Study Start:2019-09-10
Study Completion:2030-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04014374

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
  2. * Adults ≥18 years of age with either CTCL or ATLL;
  3. * AlloHCT performed from January 2012 onward.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Linda J Burns, MD
CONTACT
414-805-0714
lburns@mcw.edu
Jatin Jadwani, BDS, MSc Clinical Research
CONTACT
+49 15114861167
jatin.jadwani@kyowakirin.com

Study Locations (Sites)

CIBMTR
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Kyowa Kirin, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-09-10
Study Completion Date2030-02

Study Record Updates

Study Start Date2019-09-10
Study Completion Date2030-02

Terms related to this study

Additional Relevant MeSH Terms

  • Leukemia/Lymphoma
  • Cutaneous T Cell Lymphoma
  • ATLL